TheraCryf plc (TCF) is a biotechnology company developing novel treatments for addiction and other neuropsychiatric disorders. Its lead Ox-1 blocker programme is advancing toward first-in-human studies, targeting major unmet needs across substance use disorders and binge eating disorder. Following the announcement of positive top-line toxicology data, CEO Dr Huw Jones joins Focus IR to discuss the scientific progress, commercial potential and upcoming catalysts for the business.
In this interview, investors will hear:
- Why the latest toxicology results represent a major milestone on the path to human clinical trials
- How the Ox-1 blocker demonstrated strong tolerability at doses up to 100 times the expected human therapeutic level
- Why successful manufacturing scale-up and a new patent filing materially strengthen the programme’s commercial value
- How TheraCryf is positioning itself for future licensing opportunities in the fast-growing addiction and neuropsychiatric markets
- What catalysts investors should watch for as the Company progresses toward Phase 1 clinical trial applications in 2026
Dr Huw Jones, CEO of TheraCryf plc, was interviewed by John Hughman for Focus IR.
